The biology and management of non-small cell lung cancer

Roy S. Herbst (), Daniel Morgensztern and Chris Boshoff ()
Additional contact information
Roy S. Herbst: Yale Cancer Center, Yale School of Medicine
Daniel Morgensztern: Washington University School of Medicine
Chris Boshoff: Yale Cancer Center, Yale School of Medicine

Nature, 2018, vol. 553, issue 7689, 446-454

Abstract: Abstract Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (8)

Downloads: (external link)
https://www.nature.com/articles/nature25183 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:553:y:2018:i:7689:d:10.1038_nature25183

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature25183

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().